Exploring diabetics II inhibitors based on benzodioxin derivatives, structure activity relationship, molecular docking and ADME property study

Enzyme inhibition is one of the main target for drug development against diabetes mellitus. In this regard we have conducted the synthesis of 1,4-benzodioxin bases Schiff bases (1–25). The α-amylase activities of these compounds (1–25) found in the range of 0.60 ± 0.01 to 19.80 ± 0.40 µM when compar...

Full description

Bibliographic Details
Published in:Journal of Molecular Structure
Main Author: Al-Abdulbaqi M.A.; Taha M.; Rahim F.; Uddin I.; Uddin N.; Wadood A.; Haq S.; Iqbal N.; Khan K.M.; Ali shah S.A.; Ali M.
Format: Article
Language:English
Published: Elsevier B.V. 2024
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85186449128&doi=10.1016%2fj.molstruc.2024.137797&partnerID=40&md5=4940362cfb4e8b3e3d782ecba19bcec9
Description
Summary:Enzyme inhibition is one of the main target for drug development against diabetes mellitus. In this regard we have conducted the synthesis of 1,4-benzodioxin bases Schiff bases (1–25). The α-amylase activities of these compounds (1–25) found in the range of 0.60 ± 0.01 to 19.80 ± 0.40 µM when compared with standard acarbose (12.80 ± 0.10 µM). The α-glucosidase activity ranging from IC50 = 0.80 ± 0.01 µM to IC50 = 27.60 ± 0.60 µM when compared with standard acarbose (IC50 = 12.90 ± 0.10 µM). The structure-activity relationship (SAR) has established for all compounds. The SAR suggest that compounds containing hydroxyl and halogens are active against both enzymes. The molecular docking study was carried out to find the interaction of active compounds with enzymes. Furthermore, ADME property study is also conducted. © 2024 Elsevier B.V.
ISSN:222860
DOI:10.1016/j.molstruc.2024.137797